Icatibant Generics (Uk) (Icatibant)

Icatibant works as a selective antagonist of the bradykinin B2 receptor. It prevents bradykinin from binding to this receptor on vascular endothelial cells, thereby inhibiting the vasodilation and increased vascular permeability that lead to the fluid leakage responsible for angioedema.

The dose of Icatibant is determined by the prescribing clinician. Typically, a single subcutaneous injection is administered at the onset of an acute HAE attack, and additional doses may be given based on clinical response. Patients should follow the prescriber’s exact instructions and not adjust the dose on their own.

Safety of Icatibant in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

The primary alternative for acute HAE is a plasma‑derived C1‑esterase inhibitor (e.g., Berinert). Icatibant offers a subcutaneous, self‑administered option that works by blocking bradykinin, whereas C1‑esterase inhibitors replace the deficient protein and are given intravenously. Choice depends on patient preference, speed of onset, and clinical response.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period.

Icatibant is given as a subcutaneous injection, usually into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the solution administered using the supplied pre‑filled syringe. Patients are advised to rotate injection sites and monitor for local reactions.

Serious risks include anaphylaxis, severe hypotension, and paradoxical angioedema that can worsen swelling despite treatment. Any signs of severe allergic reaction, sudden drop in blood pressure, or unexpected swelling should prompt immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to the active substance or any of the excipients. Caution is also advised for patients with severe renal impairment or those receiving ACE inhibitors or ARBs, as the risk of bradykinin‑related adverse events may be increased.